Patients who are diagnosed with advanced or metastatic NSCLC and have EGFR mutations are the primary candidates for Tarceva. Additionally, it is used in combination with gemcitabine for treating locally advanced, unresectable, or metastatic pancreatic cancer. Genetic testing is often required to determine the presence of EGFR mutations before initiating treatment.
